{
    "code": "02023366",
    "url": "http:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02023366",
    "time": "2016-11-11 03:14:06",
    "許可證字號": "衛署藥輸字第023366號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "111\/01\/28",
    "發證日期": "91\/01\/28",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202336600",
    "中文品名": "干安能 口服液",
    "英文品名": "ZEFFIX ORAL SOLUTION",
    "適應症": "ZEFFIX適用於治療２歲以上，患有慢性B型肝炎及帶有B型肝炎病毒(HBV)複製跡象下列之病患使用慢性B型肝炎之急性發作患者因(B型肝炎病毒所致)。2.因其他疾病需接受免疫抑制治療之患者。3.需接受癌症化學療法之患者。4.需接受器官移植之患者。",
    "劑型": "170內服液劑",
    "包裝": "1000公撮以下塑膠瓶裝",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "主成分略述": [
        "LAMIVUDINE"
    ],
    "限制項目": "02輸　入",
    "申請商名稱": "0901801100  荷商葛蘭素史克藥廠股份有限公司台灣分公司",
    "主製造廠": {
        "主製造廠": "",
        "製造廠名稱": "F070037000  GLAXOSMITHKLINE INC.",
        "製造廠廠址": "7333 MISSISSAUGA ROAD NORTH MISSISSAUGA, ONTARIO CANADA L5N 6L4",
        "製造廠公司地址": "",
        "": ""
    },
    "CCC號列": "30049072004 抗人類免疫缺乏病毒感染用藥Drugs for anti human immunodeficiency virus (HIV) infections",
    "藥理治療分類": "",
    "次製造廠": [
        {
            "製造廠名稱": "F130335000  Glaxo Group Limited",
            "製造廠廠址": "980 Great West Road, Brentford, Middlesex, TW8 9GS, UK",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED KINGDOM",
            "製程": "市場許可證持有者"
        }
    ],
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "0818001400",
            "成分名稱": "LAMIVUDINE",
            "含量描述": "",
            "含量": "5.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "Zeffix OS TW PI add excipient-104-10-20.pdf",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02023366&Seq=001&Type=9"
        }
    ]
}